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Abstract.  Leukemia Inhibitory Factor (LIF) interacts 
with two classes of high affinity binding sites on rat 
UMR cells cultured in monolayer. One class of bind- 
ing sites was found to be localized in the extracellular 
matrix (ECM) after removal of cells from the culture 
dish. The interaction of LIF with ECM-localized bind- 
ing sites is not dependent upon either glycosylation of 
LIF or the presence of extracellular glycosyaminogly- 
cans. Chemical cross-linking studies demonstrate that 
LIF interacts with a 200-kD cell-associated protein 
and a  140-kD  ECM-localized protein. A  140-kD  pro- 
tein could also be specifically precipitated from solu- 
bilised metabolically radiolabeled UMR ECM by anti- 
bodies directed against LIF by virtue of its ability to 
form a stable complex with unlabeled LIE In addi- 
tion, soluble LIF associated with this ECM-localized 
protein is biologically active in terms of inhibition of 
ES cell differentiation. The properties of ECM- 
localized 140-kD  species are very similar to those of 
the secreted form of the LIF receptor suggesting that 
the ECM localization of LIF and LIF signal transduc- 
tion may be closely coupled. 
~UKEmA inhibitory factor (LIF)  ~ is a polypeptide reg- 
ulatory factor which exhibits a broad range of  biologi- 
cal activities on a wide variety of cell types in vitro. 
These include pluripotential embryonic stem cells (Smith et 
al., 1988), primordial germ cells (Matsui et al., 1992), my- 
eloid cell lines (Moreau et al., 1988; Hilton et al.,  1988), 
adipocytes (Mori et al.,  1989), hepatocytes (Baumann and 
Wong, 1989), and peripheral  neurons  (Yamamori et al., 
1989). Chronic administration of LIF to adult mice results 
in a complex syndrome which includes wasting, behavioral 
abnormalities and alterations in bone deposition (Metcalf  et 
al., 1989). The generation of homozygous LIF-/LIF- mice 
has also indicated that LIF is involved in the maternal control 
of embryonic  implantation  (Stewart et al.,  1992). These 
broad  ranging biological  actions have led to the proposal 
(Metcalf,  1991; Heath,  1990) that the action of LIF in vivo 
is confined, by some means, to a strictly local mode of  action 
within tissues. 
Analysis of LIF gene expression has revealed two forms 
of LIF transcript  which differ at their 5' end as a result of 
the use of  alternative transcriptional start sites (Rathjen et al., 
1990a). These two LIF transcripts are predicted to encode 
LIF proteins which differ at their amino terminus. A variety 
of evidence indicates that the two forms of LIF protein pro- 
duced from these alternative transcripts exhibit distinct cel- 
lular locations  and biological  activities.  First, analysis of 
LIF gene expression has revealed that the two transcripts are 
1. Abbreviations used in this paper:  ECM,  extracellular matrix, ES,  em- 
bryonic stem; FN IIl, type III fibronectin; GAG, glycosaminoglycans; LIE 
leukemia inhibitory factor. 
differentially expressed in many cell types both in vitro and 
in vivo (Rathjen et al., 1990b) suggestive of a specific role 
for each form of the protein.  Second, cells which express 
LIF transcripts initiated from the distal transcriptional  start 
site  (D-LIF)  release  LIF protein  into the culture  media 
whereas cells which express transcripts  initiated from the 
proximal start site (M-LIF) express a form of LIF which is 
tightly associated with the extracellular matrix (ECM) and 
not released into the culture media. Finally, the association 
of  LIF with the ECM has important consequences for the ac- 
tion of LIF in vivo since Conquet et al. (1992) have shown 
that the expression of M-LIF cDNAs in the preimplantation 
embryo results in arrest of gastrulation,  whereas expression 
of D-LIF cDNA has little phenotypic effect. 
While it seems clear that the association of LIF with the 
ECM has important biological consequences, the molecular 
mechanisms  underlying this  phenomenon  remain  to  be 
defined. Here we report that the association of LIF with the 
ECM of cells  cultured  in vitro  is  mediated  by a  matrix- 
localized LIF binding protein whose biochemical properties 
resemble those of the soluble form of a transmembrane  LIF 
receptor. This finding suggests that there may exist an inti- 
mate relationship between the mechanism of LIF presenta- 
tion to cells and the mechanism of target cell response. 
Materials and Methods 
Cell Culture 
UMR 106q~ cells (Allan et al.,  1990) were maintained in DME F12 sup- 
plemented with 10% FBS, 2 g/liter Na2CO3  (all from Flow Laboratories, 
Irvine, Ayrshire, Scotland), 2 mM glutamine, 50 #g/rrd streptomycin and 
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UMR 106-06 cells were responsive to LIF as determined by an inhibitory 
effect of LIF on their proliferation (data not shown). 
The embryonic stem cell (ES) cell line, El4 wild type, was cultured in 
DME F12 medium supplemented with 15% FBS, 2 g/! NazCO3, 2-mercap- 
toethanol (0.14 raM), 2 mM glutamine, 50/~g/no streptomycin, 50 IU/no 
penicillin and 10 ng/no of recombinant LIF prepared as described below. 
Cell-free ECM was prepared by detachment of cells with 0.02 % EDTA 
in PBS (Rheinwald and Green,  1975).  Extraction of matrix proteins was 
achieved by incubation of the cell-free matrix for 6 h at 4°C in a guanidium 
buffer (4 M  gnanidium-Cl, 50 mM Na-acetate, pH 6, 2% Triton X-100, 
1 mM PMSE  1 ttg/ml aprotinin), as described by Saksela et al. (1990). 
Recombinant LIF Preparation and Iodination 
Recombinant LIF (rLIF) was prepared from the prokaryotic expression vec- 
tor system pgex-2T (Pharmacia Fine Chemicals, Piscataway,  NJ). Murine 
LIF eDNA encoding for the diffusible form excluding the signal sequence, 
was cloned into the pgex-2T plasmid at the BamHI site of the pelylinker. 
This allowed for inducible expression of  a glutathione-S-transferase-LIF  fu- 
sion protein (gex-LIF), whereby the LIF protein is fused to the COOH- 
terminus of gex protein from Schistasoma japonicum. Intracellular fusion 
protein (gex-LIF) was recovered from E. coli lysates by affinity chromatog- 
raphy using a glutathione Sepharose gel matrix (Smith and Johnson, 1988). 
Pure recombinant LIF was isolated from this system by cleavage of the fu- 
sion protein by thrombin at a unique site introduced between the glutathione 
and LIF protein junction. This LIF was further purified by reverse phase 
HPLC using a reverse phase C8 column (Ultrapore RPMC; Beckman In- 
struments, Inc., Fullerton, CA). The column was equilibrated with 0.1% 
TFA/20% Acetonitrile and acidified samples were applied at a flow rate of 
1 no/rain. After washing the column with 0.1% TFA/20% acetonitrile, rou- 
tine LIF was eluted with a linear gradient of 20-70% acetonitrile, at a 1% 
incremental increase of acetonitrile per non for 60 non. Murine LIF einted 
from the column at a nominal gradient of 0.1% TFA/47 % acetonitrile. This 
material was purified to homogeneity as determined by SDS-PAGE, with 
a relative molecular mass of 20 kD. Biological activity of the purified pro- 
tein was assessed by its inhibitory effect on ES differentiation (Smith et al., 
1988) and its proliferative effect on DA-la cells (Moreau et. al., 1988),  its 
specific activity  in  the  latter  was  determined to  be  1--4  x  106  U/rag 
(whereby one unit of  LIF activity is defined as the amount required to induce 
a half-maximal proliferative response of DA-Ia cells). 
Purified recombinant LIF was  iodinated using the Iodo-gen method 
(Fraker and Speck, 1978). LIF (3 ttg) in 0.1 M phosphate buffer, pH 7, con- 
taining 1% PEG was added to a tube precoated with 1 t~g Iodo-gen (Pierce, 
Rockford, IL). Carrier-free [1251] (1 mci; A.S.:15 mCi/#g, Amersham In- 
ternational, Buckinghamshire, England) was added to the mixture and in- 
cubated 20  rain  at  room temperature.  The  reaction was terminated by 
removing the solution from the tube and renaturation of the protein was 
achieved by addition of DTT to a final concentration of 12.5 mM. lzSI-LIF 
was separated from unbound [n51]  by gel filtration through a  Sephadex 
G-25 column (PD-10,  Pbarmacia Fine Chemicals) pre-equilibrated with 
PBS containing 0.1% BSA. Fractions were monitored for radioactivity and 
those eluting in the void volume were pooled and stored at 40C. Preparation 
of 125I-LIF used for experiments in this paper had specific activity in the 
range of 2--4 x  10  is dpm/mol. Radiolabeled 125I-LIF was determined to be 
biologically active as measured by differentiation inhibition assays on Em- 
bryonic Stem (ES) cells (Smith et al.,  1988). 
Polyclonal Antibodies 
Gex-LIF fusion protein was used to inoculate rabbits for the generation of 
polyclonal anti-LIF antibodies. Bound gex-LIF fusion protein (as described 
above) was released from the glutathione Sepharose matrix by direct ex- 
change with reduced glutathione (1 mM) and then further purified by elec- 
troelution from an SDS-polycrylamide gel.  Specific recognition of anti- 
serum  to  the  LIF  protein  was  verified  by  Western blot  analysis  and 
immunoprecipitation experiments (results not shown) whereby anti-LIF se- 
rum immuneprecipitated a 43-kD species in the supernatant of cos cells 
transfected with the LIF gene that was not resolved by pre-immune serum. 
Anti-fibronectin, anti-transferrin receptor, and anti-vinculin antibodies 
used to perform Western blot analyses were all obtained from Sigma lm- 
munochemicals. 
Radioligand Binding Analysis 
Binding assays were performed on confluent adherent monoloayers of UMR 
cells grown in 5-cm-diam dishes (5 x  106 cells per dish) in 2 n0 of binding 
buffer (DME containing 25 mM Hepes, pH 7.4, 0.1% BSA, 0.1 mM PMSF, 
and  1 /~g/ml each of aprotinin, leupoptin, and pepstatin). Cells were in- 
cubated with increasing amounts of radiolabeled LIF with or without a 500 
fold excess of unlabeled LIE in duplicate for 3 h at 4°C. Cells were then 
washed twice with cold binding buffer and once with binding buffer contain- 
ing 0.2 M NaCI. Cells were removed from the dishes with a lysis buffer (20 
mM Hepes, pH 7.4, 0.15 M NaC1,  1 mM MgCI2, 1 mM CaC12, 1% Triton 
X-100) and cell-bound radioactivity was determined by measurement in a 
gamma counter (LKB Instruments Inc., Newbury Park, CA). Specific bind- 
ing was calculated by subtracting radioactivity bound in the presence of 
excess unlabeled LIF from total binding. Generally, nonspecific binding 
represented 25-30 % of maximal binding. Variation between replicated de- 
terminations was <10 %. For determination of binding constants, saturation 
binding data were analyzed using the LIGAND fitting program (Munson 
et al.,  1980). 
To achieve chemical cross-linking of  proteins on cells, cells were washed 
once with binding buffer without BSA after the binding reaction. The cross- 
linking reaction was initiated by addition of N-hydroxy-sulfosuecinimide 
(SUlpho-NHS; Pierce) (5 mM) and 1-ethyl-3-(3-dimethylaminopropyl)  car- 
bodiimide (El)C, Pierce) (20 raM). The reaction was performed in binding 
buffer (without BSA) during a 30-rain incubation at 4°C and then quenched 
by addition of 10 mM tris-C1, pH 7.4, containing 10 mM glyeine. After ex- 
teusive washing with cold binding buffer, cells were sohibilized with 0.1 no 
SDS sample buffer (Laemmli, 1970),  sonicated for 30 s to reduce viscosity, 
and analyzed by SDS-PAGE. 
Cell Labeling, Lysis, and lmmunoprecipitation 
For metabolic labeling with [35S]methionine,  subconfluent cells grown in 
10-cm-diam dishes were washed twice with PBS, and then serum-starved 
in 2 ml methionine-free modified MEM, supplemented with 5% dialyzed 
FBS (GIBCO BRL, Gaithersburg, MD) for 30 rain at 37"C. [3SS]methio- 
nine (90 ~tCi/no;  A.S.:I,000 Ci/mmol; Amersham) was then added and 
ceils were metabolically labeled overnight. After labeling, cell supernatants 
were collected and clarified by centrifugation for 30 rain at 4"C. 
For immunoprecipitation of matricial proteins from [35S] radiolabeled 
cell-free ECM, guanidium was first exchanged for 8 M urea by gel filtration 
through a Sepharose G-25 column that had been pre-equilibrated with 8 M 
urea in 50 mM Na-acetate buffer, pH 6, containing 0.5 % Triton X-100, 0.15 
M NaCI, 1 mM PMSF, 1 t~g/ml each of aprotinin, leupeptin and pepstatin, 
and then eluted with the same buffer. The eluted radiolabeled material was 
pooled and the sample was adjusted with 50 mM Na-acetate, pH 6, to a 
final concentration of 2 M urea. 
Before immunoprecipitation with polyelonai antibodies to LIE clarified 
supernatant and matrix extract were precleared by incubation with protein 
A-Sepharose (100/zl of 10% suspension [vol/vol]; CL4B; Pharmacia Fine 
Chemicals) for 30 non at 4°C. Supernatants were transferred to new tubes 
containing crude anti-LIF antiserum at 1:100 final dilution and incubated 
for 2 h at 4°C. As controls, equivalent amounts of pre-immune serum were 
used. Protein A-Sepharose (100/d of 10% suspension) was then added. Af- 
ter a further 2-h incubation at 4"C, immune complexes were centrifuged 
through a sucrose gradient (10-20%), washed twice with 0.1 M NaC1,  10 
mM tris-Cl, pH 8, 0.1%  NP-40, 0.1%  SDS, resuspended in SDS-sample 
buffer, heated to  100*C  for 3 rain, and then electrophoretieally resolved 
through polyacrylamide gels containing SDS. 
Results 
Characterization and Localization of  LIF 
Binding Sites 
The purification and amino acid sequencing of LIF from the 
ECM of cells which express predominantly M-form tran- 
scripts has revealed that the protein exists in the matrix in 
its mature form lacking the secretory signal sequence (Rath- 
jen et al., 1990a). This finding suggested that the association 
of LIF protein with the ECM is an inherent property of the 
mature form of LIF protein. Thus, we accordingly examined 
the ability of exogenous LIF to associate with the ECM of 
cultured cells.  For the purposes of these experiments we 
used, as a ligand, recombinant nonglycosylated murine LIF 
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Figure 1. High and low affinity binding sites on UMR 106-06 cells. 
Scatchard analysis of one of the three saturation experiments per- 
formed on ceils grown on their matrix. (Inset) Saturation curve for 
specific binding (n  =  3). 
produced in bacteria which corresponds in sequence to the 
mature form of the protein with the addition of two amino 
acid residues at the NH2-terminus and as a target cell, rat 
UMR osteosarcoma ceils. UMR ceils have been reported to 
express relatively high numbers of LIF receptors but have 
low  levels  of endogenous  LIF  expression  (Allan  et  al., 
1990). 
The expression of specific LIF binding sites on UMR cells 
grown in monolayer was examined by radioligand binding 
assay using  |25I-labeled LIE A  scatchard transformation of 
the binding  isotherm of LIF to  UMR  cells,  applying the 
LIGAND  curve  fitting  program  (Munson  et  al.,  1980; 
Draper and Smith,  1966), revealed two classes of binding 
sites  (Fig.  1):  a  majority class  (apparent  Kd  =  1-5  nM, 
5,000-20,000  sites/cell) and a  minority class (apparent Kd 
=  10-100 pM, 200-1,000 sites/cell). These findings are in 
accord with previous studies of LIF binding sites expressed 
by UMR and other cells (Hilton et al.,  1988,  1991; Godard 
et al., 1992) but do not distinguish between LIF binding sites 
associated with cells or associated with the ECM. Cell-free 
ECM preparations of UMR cells were derived from mono- 
layer cultures in which the ceils had been removed after dis- 
persal with EDTA. Immunochemical analysis of the residual 
ECM associated with the culture dish indicated that it was 
significantly depleted in marker proteins corresponding to 
either cell membranes (transferrin receptor) or cytoskeleton 
(vinculin) but did contain the ECM located protein fibronec- 
tin (data not shown). A comparison of the specific binding 
of J25I-LIF to either intact cell monolayers or to the cell- 
free ECM preparation revealed that ~35% of the total spe- 
cific binding was derived from binding to the ECM (Fig. 2). 
These  extracellular LIF  binding  sites  were derived from 
UMR cells since the specific binding to virgin tissue culture 
plastic  was  insignificant.  Since it is  well established  that 
other growth factors may associate with the ECM by means 
of association with the extracellular carbohydrate side chains 
of glycosaminoglycans  (GAGs)  (Vlodavsky  et  al.,  1987; 
Andres et al.,  1990) we examined the effect of treating the 
Figure 2. Specific binding of t~I-LIF to ECM is not abolished by 
digestion of glycosaminoglycans. Binding of I~I-LIF (5 nM) is ex- 
pressed as the percentage of  the total amount of  radioactivity bound 
to ceils  grown on their matrix,  both total (,,)  and  nonspecific 
([]) binding are shown for each growth condition as well as the 
background due to the plastic (n). Total binding to matrix,  pre- 
treated for 3 h. with 10 IU/dish of either heparinase or chondroi- 
tinase is represented respectively, by ffa) and ([]).  Non-specific 
binding has been estimated in the presence of a 500 fold excess of 
rLIE 
cell-free ECM preparation with heparinase and chondroi- 
tinase.  Digestion of extracelluar GAGs had no significant 
effect on the specific binding of 125I-LIF to UMR-derived 
ECM preparations (Fig. 2) indicating that the mechanism of 
LIF association with the ECM does not involve extracellular 
GAGs. Taken together, these findings demonstrate that exog- 
enous LIF can form a specific complex with components of 
the ECM by means of a mechanism that does not involve the 
direct participation of carbohydrate side chains. 
The molecular identity of  the specific LIF binding sites ex- 
pressed by UMR cells was further characterized by chemical 
cross-linking  studies.  UMR  cell  monolayers  or  cell-free 
ECM preparations were incubated under equilibrium bind- 
ing conditions with 125I-LIF over a range of concentrations 
from 500 pM to 125 pM followed by cross-linking with both 
Sulpho-NHS and EDC.  The results of the experiments are 
shown  in  Fig.  3.  When  125I-LIF is  cross-linked  to  cells 
grown  in  monolayer,  two  prominent  and  specific  cross- 
linked species of 200 and 140 kD (after subtraction of 20 kD 
for the molecular mass of LIF) are detected. There is in addi- 
tion  a  much  fainter species of an approximate molecular 
mass of 350 kD apparent at high concentrations of 125I-LIE 
Chemical cross-linking of 125I-LIF to cell-free ECM prepa- 
rations, by contrast, reveals a single cross-linked species of 
140 kD with only trace amounts of the 200-kD species de- 
tectable at the highest concentrations of ~25I-LIF and no evi- 
dence for any larger species. This strongly suggests that the 
200-kD species is cell-associated and the 140-kD species is, 
at least in part, extracellular and ECM-associated. Although 
these experiments do not permit precise quantification of the 
affinity of ~25I-LIF for these species, a comparison of the in- 
tensity of cross-linked bands at different concentrations 3f 
LIF  suggests  that  the  140-kD  species  is  recognized with 
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ing  of  nSI-LIF  to  UMR- 
derived ECM and cells. Typi- 
cal  experiment.  Similar  re- 
sults  were  obtained  in  two 
other experiments  performed 
with  UMR  cells  as  well  as 
with other cell lines (PYS and 
P19 cells). 
somewhat lower affinity than the 200-kD species. These con- 
siderations  suggest that  the  association of exogenous LIF 
with the ECM arises as a result of the formation of a specific 
complex with an ECM localized molecule of 140 kD and that 
Figure 4. Co-immunoprecipitation  of 35S-labeled LIF-binding pro- 
tein from UMR-derived cell-free  ECM with anti-LIF antiserum. 
Immunoprecipitation  with  either  anti-LIF  antiserum  or  pre- 
immune serum (PI) of UMR cell supernatant  and UMR-derived 
cell-free ECM extract in presence or absence of exogeneous rLIF 
(5 nM). 
the high affinity sites (Kd =  50 pM) detected by binding to 
cell monolayers results in part from LIF association with the 
200 kD (and 350 kD) species. 
Co-immunoprecipitation Analysis 
The above data indicates  that radiolabeled exogenous LIF 
binds specifically to an ECM-localized species of 140 kD. 
As a complementary approach to this issue, we investigated 
the association of radiolabeled ECM components with unla- 
beled LIF using the ability of antibodies directed against ma- 
ture LIF to co-precipitate LIF binding proteins. UMR cells 
were metabolically radiolabeled with [35S]methionine  and a 
cell-free ECM prepared by removal of the cells with EDTA 
as before. The radiolabeled ECM extract was then incubated 
with 5  nM unlabeled LIE This concentration was selected 
on the basis that it was about twofold higher than the Kd of 
the majority LIF binding sites detected by whole cell radio- 
ligand binding assay and equivalent to the concentration used 
in the analysis of LIF binding to cell-free ECM preparations 
shown in Fig. 2. The extracts were immunoprecipitated with 
anti-LIF  antibodies  immobilized on  protein  A-Sepharose 
and analyzed by SDS-PAGE and autoradiography (Fig. 4). 
A  single  radioactive  species  was  precipitated  from the 
35S-labeled cell-free ECM extract with an apparent molecu- 
lar mass of 140 kD. Immunoprecipitation of this species with 
anti-LIF antibodies was dependent upon previous co-incu- 
bation of the ECM extract with unlabeled LIF demonstrating 
that the 140-kD species was immunoprecipitated as a conse- 
quence of its affinity for soluble LIE This species was not 
detected in culture supernatants subjected to the same proce- 
dures suggesting that this protein was predominantly local- 
ized in the cell-free ECM material associated with the tissue 
culture plate after removal of the cells. 
The results of this experiment are therefore in accord with 
the results of chemical cross-linking studies in that they indi- 
cate that LIF can form a specific complex with a protein of 
140 kD located in the ECM of UMR cells. 
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differentiation. ES cells  (103 cell/well) were cultured on UMR- 
ECM which was previously incubated for 3 h with (B) or without 
rLIF (10 ng/ml) (A) and then extensively washed with LIF-free 
medium. As a control, ES cells were grown to the same density in 
absence of ECM and in presence of rLIF (10 ng/ml) (C). After a 
5-d incubation at 37°C in a humidified atmosphere, cultures were 
fixed and stained for alkaline phosphatase activity using the Sigma 
kit 86-R. Bar, 100 #m. 
Biological Relevance 
To determine whether the specific association of LIF to the 
140-kD ECM-localized protein was biologically active, this 
complex was tested for its ability to support growth of ES 
cells in an undifferentiated state (Smith et al.,  1988). UMR 
matrix was pre-incubated in presence or in absence of exoge- 
nous LIF (to binding equilibrium), washed extensively and 
then used as a growth support for ES cells. These cultures 
were then stained for alkaline phosphatase (APase) activity, 
as a  marker of undifferentiated ES cells (Bernstine et al., 
1973).  ES  cells  grown  on  pure  UMR-ECM  underwent 
differentiation as in LIF-free medium (Fig. 5 A). This result 
confirms that UMR cells do not produce matrix-associated 
LIE In contrast, ES cells grown on UMR matrix that was 
pre-incubated with exogenous LIF, remained undifferenti- 
ated (Fig. 5 B) and grew in discrete colonies with typical ES 
morphology and APase expression in an equivalent manner 
to control cells cultured in the presence of soluble LIF (Fig. 
5  C).  Nonspecific interactions with matrix components or 
plastic cannot account for the retention of LIF since in con- 
trol experiments performed with ECM-derived from either 
human or sparse UMR cells (104 cells/cm2), ES underwent 
differentiation (data not shown). Hence, LIF retained in the 
ECM by its association with the 140-kD protein is able to 
invoke a biological response. 
Discussion 
The experiments reported above demonstrate that the associ- 
ation of LIF with the ECM involves the formation of specific 
complex between LIF and an extracellular binding protein 
in the ECM since it is insensitive to heparinase and chon- 
droitinase digestion. This binding protein can be identified 
by  chemical  cross-linking  of  125I-LIF to  ECM  localized 
sites or by co-precipitation by anti LIF antibodies and has 
a molecular weight of 140 kD.  The chemical cross-linking 
experiments have also  identified,  in  addition to  an  ECM 
localized binding protein, a LIF binding protein of 200 kD 
which is cell associated and significantly depleted from the 
culture dish by removal of the cells. Cross-linking to whole 
cells has also indicated the existence of an additional minor 
component  of  350  kD.  Moreover,  soluble  LIF  retained 
specifically by the 140-kD protein located in the ECM is bio- 
logically active. Two important issues are therefore the mo- 
lecular identity of these LIF binding proteins and their func- 
tion in terms of LIF bioactivity. 
Gearing et al. (1991) have reported the molecular cloning 
of a transmembrane protein which binds LIF with an affinity 
comparable  to  the  "low  affinity" class  of LIF  receptors 
reported here and in other studies (Hilton et al.,  1988 and 
1991; Godard et al., 1992). This molecule (hereafter termed 
LIF-R) has an apparent molecular mass of 190 kD and on 
the basis of its sequence relatedness to other receptors is a 
good candidate for a transmembrane LIF signal transducing 
receptor. Godard et al. (1992) have also identified, by chemi- 
cal cross-linking of radiolabeled LIF to cells in suspension, 
a  LIF receptor of •  250 kD.  It would appear most likely 
therefore that  the  200-kD  species  identified by chemical 
cross-linking  experiments  corresponds  to  the  transmem- 
brane form of the LIF receptor described by Gearing et al. 
(1991). Co-expression of the IL-6 receptor associated trans- 
membrane protein gp130 with LIF-R has revealed an interac- 
tion between LIF-R and gp130 which results in the formation 
of "high affinity" binding sites of similar affinity to the high 
affinity (Kd =  50 pM) class of binding sites observed in in- 
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350-kD  species detected in our cross-linking experiments 
might therefore represent a  complex between the 200-kD 
LIF-R and gpl30. 
The  ECM-localized LIF binding protein  reported here 
differs from the  transmembrane  receptor  LIF-R both  in 
terms of  molecular mass and its extracellular localization but 
interacts directly with LIE In the course of isolating the 
transmembrane LIF-R, Gearing et al. (1991) isolated addi- 
tional cDNA clones which encoded a truncated form of the 
LIF-R with a  predicted molecular mass of 140  kD.  This 
"secreted" form of the receptor (sLIF-R) yields a LIF-R spe- 
cies lacking the intracellular and transmembrane domains as 
well as one copy of the three type HI fibronectin (FN III) re- 
peat sequences of the extracellular domain.  Recombinant 
sLIF-R was,  in addition,  found to  remain physically as- 
sociated with cells when expressed under the control of a 
heterologous promoter in COS cells (Gearing et al., 1991). 
An attractive hypothesis is therefore that the 140 kD ECM- 
localized species reported here is, in fact, the sLIF-R trun- 
cated form of the transmembrane LIF receptor. 
Two other candidate proteins for the EeM-localized LIF 
binding protein exist. Layton et al. (1992) have reported the 
isolation of a 90-kD LIF binding protein from normal mouse 
serum based upon its ability to inhibit both the binding of 
radiolabeled LIF to target cells and its biological activity. 
The molecular mass of this protein would seem to be too low 
to represent any of the LIF binding proteins identified in this 
study. However,  sequence analysis of this protein revealed 
that it was a truncated form of the LIF receptor lacking 48 
residues at the amino terminus. If this molecule is derived 
from the secreted 140-kD  sLIF-R it would seem probable 
that the protein is also truncated at the carboxy terminus, in 
the region of the FN III domains, to account for its reduced 
mass compared to the sLIF-R. This might indicate that the 
FN III domains may play some role in anchoring the sLIF-R 
(and therefore LIF) in the ECM and that the sLIF-R is sub- 
jected to further processing which controls its extracellular 
dissemination. 
Under conditions which favored binding to the high af- 
finity class of cell-associated LIF receptors, Godard et al. 
(1992) identified a species of 120 kD by cross-linking experi- 
ments. A similar protein has been determined to be a sub- 
strate for tyrosine phosphorylation induced in response to 
exposure of cells to LIF (Ip et al.,  1992).  In the latter case 
this molecule has been identified as gp130. It is unlikely, on 
two grounds, that the 140-kD species identified in this study 
and localized in the ECM is gpl30. First, gpl30 is a trans- 
membrane protein and would be expected to be depleted 
when cells are removed from the culture dish. Second, there 
is strong evidence that LIF does not bind gpl30 directly but 
rather gpl30 binds to a complex of LIF and the LIF-R to 
form the high affinity class of binding sites (Gearing et al., 
1992; Bruce et al., 1992). The ECM-localized 140-kD spe- 
cies appears to interact with LIF with lower affinity than cell 
associated binding sites and interacts directly with LIE Our 
inability to detect the 120-kD  species described by Godard 
et al. (1992) may well reflect the different cross-linking agents 
used in the two studies. 
Taking these considerations together, therefore, we favor 
the hypothesis that the ECM localized LIF binding protein 
is, in fact, the secreted form of  the LIF-R described by Gear- 
ing et al. (1991). Conclusive proof of this possibility will re- 
quire further experimentation, however, the hypothesis is at- 
tractive  since  it  provides  a  biological  function  for  this 
molecule; the control of delivery of LIF protein to target 
cells by sequestration of the factor in the ECM. These data 
not only provide a molecular mechanism for eliciting local 
action of LIF in vivo but also argue that ECM sequestration 
of LIF is intimately associated with the mechanics of LIF 
signal transduction. 
Soluble  forms  of  growth  factor  receptors  have  been 
reported in a number of cases including receptors which are 
related in structure to the LIF-R, the "bemopoietin receptors 
family: These include among others the receptors for IL-4, 
IL-5, IL-6, IL-7, and G-CSF (Mosley et al., 1989;  Takaki 
et  al.,  1990;  Taga  et  al.,  1989;  Goodwin et  al.,  1990; 
Fukunaga et al.,  1990).  It has been widely assumed that 
soluble receptors compete for ligand with transmembrane 
receptors and may therefore be antagonistic in function (Mal- 
iszewski et al., 1990; Layton et al., 1992). There are indica- 
tions, however,  that at least some ligand/soluble receptor 
complexes can be biologically active. Taga et al. (1989) have 
also demonstrated that a complex between IL-6 and its solu- 
ble receptor can elicit biological effects on target cells which 
do not themselves express the transmembrane form of the 
IL-6 receptor.  Another example is the glycosyl-phospha- 
tidylinositol-linked CNTF-R which is part of a  functional 
and biologically active complex (Ip and Yancopoulos,  1992). 
It is also clear that LIE in its ECM-associated form, is bio- 
logically active at least in terms of its ability to suppress ES 
cell differentiation. This would suggest that the association 
between LIF and the sLIF-R may represent a biologically ac- 
tive complex and that cells may be able to respond to LIF 
without requiring expression of the transmembrane form of 
the LIF-R. 
Irrespective of these considerations, the data presented in 
this paper have demonstrated that the association of LIF with 
the ECM is an inherent property of the mature LIF protein 
and is brought about by an interaction between LIF and an 
ECM-localized binding protein. The studies have also shown 
that LIF is capable of associating with the ECM of cells that 
do not themselves express appreciable levels of M-LIF and 
is, in this context, biologically active. This implies that LIF 
can associate with the ECM if it has access to the ECM- 
localized binding protein. The role of the alternative amino 
termini may therefore be to regulate access to the ECM bind- 
ing protein during biosynthesis of the nascent LIF protein. 
Equally the ECM localization of LIF requires the expression 
of the binding protein which can, in principle, be provided 
by a heterologous cell type. The phenomenon of ECM local- 
ization may extend beyond the expression of alternative LIF 
transcripts under in vivo conditions where beterologous cell 
types are in close physical proximity. 
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